A Phase Ia/Ib, SAD and MAD Study of of KL1333 in Healthy Subjects and Patients With Primary Mitochondrial Disease
Status:
Completed
Trial end date:
2021-03-16
Target enrollment:
Participant gender:
Summary
This will be a double blind, randomised, placebo controlled, single and multiple oral dose
study conducted in 3 parts: Part A, Part B and Part C. Part A and Part B include healthy
volunteers only and will be completed before Part C including patients with primary
mitochondrial disease will be initiated. The starting dose in the first cohort of Part A will
be 25 mg. The dose level in the additional cohorts will be decided following review of data
of the previous cohorts.